Onset timing of statin‐induced musculoskeletal adverse events and concomitant drug‐associated shift in onset timing of MAE s
To evaluate the onset timing of musculoskeletal adverse events ( MAE s) that develop during statin monotherapy and to determine whether concomitant drugs used concurrently with statin therapy shifts the onset timing of MAE s. Cases in which statins (atorvastatin, rosuvastatin, simvastatin, lovastati...
Gespeichert in:
Veröffentlicht in: | Pharmacology research & perspectives 2018-12, Vol.6 (6) |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | To evaluate the onset timing of musculoskeletal adverse events (
MAE
s) that develop during statin monotherapy and to determine whether concomitant drugs used concurrently with statin therapy shifts the onset timing of
MAE
s. Cases in which statins (atorvastatin, rosuvastatin, simvastatin, lovastatin, fluvastatin, pitavastatin, and pravastatin) were prescribed were extracted from the
US
Food and Drug Administration (
FDA
) Adverse Event Reporting System (
FAERS
) Data Files. The onset timing of
MAE
s during statin monotherapy was evaluated by determining the difference between statin start date and
MAE
onset date. The use of concomitant drugs with statin therapy was included in the analysis. Statins used in combination with concomitant drugs were compared with statin monotherapy to determine if the use of concomitant drugs shifted the onset timing of
MAE
s. The onset of
MAE
s was significantly faster with atorvastatin and rosuvastatin than with simvastatin. A difference in onset timing was not detected with other statins because the number of cases was too small for analysis. When evaluating concomitant drug use, the concomitant drugs that shifted the onset timing of
MAE
s could not be detected. Statins with strong low‐density lipoprotein cholesterol‐lowering effects (atorvastatin and rosuvastatin) contributed not only to a high risk of
MAE
onset, but also to a shorter time‐to‐onset. No concomitant drug significantly shifted the onset timing of
MAE
s when used concurrently with statins. |
---|---|
ISSN: | 2052-1707 2052-1707 |
DOI: | 10.1002/prp2.439 |